United States: Federal Circuit Affirms Obviousness Of Rifaximin Polymorph Patents And Denial Of Motion To Modify Judgment After Post-Trial Patented Indication Carve Out - Mintz
In a precedential opinion issued on April 11, 2024 in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Nos. 22-2153, 23-1952, the U.S. Court of Appeals...
Full Article